TABLE 1B.

Change in the alkaline phosphatase values for the active drug and placebo groups in the key phase 2 and 3 trials in PBC

Trial agent	Maximum percentage change in ALP in active drug group from baseline	Percentage improvement in ALP in the placebo group from baseline
OCA phase 224	−25	−3
OCA phase 3 (“POISE”)16	−41	−4
OCA phase 3 confirmatory (“COBALT”) (12-month data)25	−28	−18
Bezafibrate phase 317	−60	0
Elafibranor phase 3 (“ELATIVE”)21	−39	1.7
Seladelpar phase 3 (“ENHANCE”)20	−42	0
Budesonide phase 226	−29	−2.5

Abbreviation: ALP, alkaline phosphatase.